Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Feb 2024 Status changed from active, no longer recruiting to completed.
14 Nov 2023 Results assessing the effect of lanifibranor on IR in liver, muscle and adipose tissue in relation to intrahepatic triglyceride (IHTG) content presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
13 Jun 2023 According to an Inventiva Pharma Media Release, additional secondary endpoints including a series of markers of cardiometabolic health are anticipated to be presented by Dr. Cusi in upcoming scientific conferences and publications

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com